Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Hemab Therapeutics Surges to New High on Analyst Backing

Guavy AI Editorial Team
Instruments
GS
Share

Hemab Therapeutics (NASDAQ:COAG) reached a new 52-week high on Thursday, trading as high as $52.29 and closing at $51.07 with a volume of 38,258 shares.

The company's stock has received positive ratings from analysts, including upgrades from Zacks Research to 'hold', Jefferies Financial Group's increase in price target to $47.00, and The Goldman Sachs Group's initiation of coverage with a 'buy' rating and a target price of $36.00.

The average analyst rating is currently 'Moderate Buy' with an average price target of $48.00.

More on Stocks

Stocks 4m ago

JPMorgan CEO Warns Market Leverage at 'Pretty High' Levels

Stocks 4m ago

JPMorgan Chase Surpasses Q2 Earnings Expectations

Stocks 8m ago

Capital One Offers Huge Rewards on Purchases Ahead of Expiration Deadline

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy